Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001104659-24-108134 0001714576 XXXXXXXX LIVE 3 Common Stock, par value $0.0001 per share 05/02/2025 false 0001740279 45674E109 IN8bio, Inc. EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 Bios Equity Partners, LP (817) 984-9197 1751 River Run, Suite 400 Fort Worth TX 76107 Rick Jordan; Polsinelli PC (214) 397-0030 2950 N. Harwood St., Suite 2100 Dallas TX 75201 0001714576 N BIOS FUND II, LP b WC N DE 0.00 574432.00 0.00 574432.00 574432.00 N 0.6 PN Percentage based on 90,771,944 outstanding shares as of May 2, 2025, provided by Issuer. 0001716869 N BIOS FUND II QP, LP b WC N DE 0.00 1876624.00 0.00 1876624.00 1876624.00 N 2.1 PN Percentage based on 90,771,944 outstanding shares as of May 2, 2025, provided by Issuer. 0001728851 N BIOS FUND II NT, LP b WC N DE 0.00 251211.00 0.00 251211.00 251211.00 N 0.3 PN Percentage based on 90,771,944 outstanding shares as of May 2, 2025, provided by Issuer. 0001740029 N BIOS INCYSUS CO-INVEST I, LP b WC N DE 0.00 997433.00 0.00 997433.00 997433.00 N 1.1 PN Percentage based on 90,771,944 outstanding shares as of May 2, 2025, provided by Issuer. 0001791917 N BIOS FUND III, LP b WC N DE 0.00 570724.00 0.00 570724.00 570724.00 N 0.6 PN Percentage based on 90,771,944 outstanding shares as of May 2, 2025, provided by Issuer. 0001791916 N BIOS FUND III QP, LP b WC N DE 0.00 3727597.00 0.00 3727597.00 3727597.00 N 4.1 PN Percentage based on 90,771,944 outstanding shares as of May 2, 2025, provided by Issuer. 0001791910 N BIOS FUND III NT, LP b WC N DE 0.00 601980.00 0.00 601980.00 601980.00 N 0.7 PN Percentage based on 90,771,944 outstanding shares as of May 2, 2025, provided by Issuer. 0001988639 N BIOS CLINICAL OPPORTUNITY FUND, LP b WC N DE 3140803.00 0.00 3140803.00 0.00 3140803.00 N 3.3 PN Shared voting and dispositive power includes a total of 3,140,803 shares of common stock, par value $0.0001 per share ("Shares") issuable upon the exercise of warrants directly held by Bios Clinical Opportunity Fund, LP ("Bios COF"), consisting of 2,431,763 pre-funded warrants and 709,040 Series C warrants as of the date hereof (together, the "Bios COF Warrants"). All of the Bios COF Warrants are exercisable as of the date hereof. However, each of the Bios COF Warrants is subject to a restriction on exercise to the extent the beneficial ownership of the Reporting Persons would exceed 9.99% (the "Beneficial Ownership Limitation"). 0001813311 N BP DIRECTORS, LP b OO N DE 0.00 121775.00 0.00 121775.00 121775.00 N 0.1 PN Shared voting and dispositive power consists of 121,775 Shares issuable upon exercise of options granted in consideration for Travis Whitfill's services as a director of the Issuer, which are exercisable or will be immediately exercisable within 60 days of the date hereof (the "Bios Directors Options"). Pursuant to an agreement with BP Directors, LP ("Bios Directors"), Mr. Whitfill has agreed that he will hold certain equity-based awards granted to him in connection with his services as a director of the Issuer while affiliated with Bios Directors (including the Bios Directors Options) merely as a nominee for Bios Directors. Mr. Whitfill is not currently an affiliate of any of the Reporting Persons. Percentage based on 90,893,719 Shares, consisting of (i) 90,771,944 Shares outstanding as of May 2, 2025, provided by Issuer, and (ii) 121,775 Shares issuable upon exercise of the Bios Directors Options. 0001813314 N BIOS EQUITY PARTNERS, LP b AF N TX 0.00 121775.00 0.00 121775.00 121775.00 N 0.1 PN Percentage based on 90,771,944 outstanding shares as of May 2, 2025, provided by Issuer. Shared voting and dispositive power consists of 121,775 Shares issuable upon exercise of the Bios Directors Options. Bios Equity Partners, LP ("Bios Equity I") is the general partner of Bios Directors. In its capacity as the general partner of Bios Directors, Bios Equity I may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by Bios Directors. Percentage based on 90,893,719 Shares, consisting of (i) 90,771,944 Shares outstanding as of May 2, 2025, provided by Issuer, and (ii) 121,775 Shares issuable upon exercise of the Bios Directors Options. 0001813313 N BIOS EQUITY PARTNERS II, LP b AF N TX 0.00 3699700.00 0.00 3699700.00 3699700.00 N 4.1 PN Percentage based on 90,771,944 outstanding shares as of May 2, 2025, provided by Issuer. Shared voting and dispositive power consists of of (i) 574,432 Shares directly held by Bios Fund II, LP ("Bios Fund II"), (ii) 1,876,624 Shares directly held by Bios Fund II QP, LP ("Bios Fund II QP"), (iii) 251,211 Shares directly held by Bios Fund II NT, LP ("Bios Fund II NT") and (iv) 997,433 Shares directly held by BIOS Incysus Co-Invest I, LP ("BIOS Incysus"), in each case, as of the date hereof. Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, Bios Fund II QP, Bios Fund II NT and BIOS Incysus. In its capacity as the general partner of these entities, Bios Equity II may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by these entities. 0001831976 N BIOS EQUITY PARTNERS III, LP b AF N TX 0.00 4900301.00 0.00 4900301.00 4900301.00 N 5.4 PN Percentage based on 90,771,944 outstanding shares as of May 2, 2025, provided by Issuer. Shared voting and dispositive power consists of of (i) 570,724 Shares directly held by Bios Fund III, LP ("Bios Fund III"), (ii) 3,727,597 Shares directly held by Bios Fund III QP ("Bios Fund III QP"), and (iii) 601,980 Shares directly held by Bios Fund III NT ("Bios Fund III NT"), in each case, as of the date hereof. Bios Equity Partners III, LP ("Bios Equity III") is the general partner of Bios Fund III, Bios Fund III QP and Bios Fund III NT. In its capacity as the general partner of these entities, Bios Equity III may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by these entities. 0002000747 N BIOS EQUITY COF, LP b AF N TX 3140803.00 0.00 3140803.00 0.00 3140803.00 N 3.3 PN Shared voting and dispositive power includes a total of 3,140,803 Shares issuable upon the exercise of the Bios COF Warrants that are not currently exercisable due to the Beneficial Ownership Limitation. Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF. In its capacity as the general partner of Bios COF, Bios Equity COF may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by Bios COF. 0001813270 N CAVU MANAGEMENT, LP b AF N TX 0.00 8721776.00 0.00 8721776.00 8721776.00 N 9.6 PN Shared voting and dispositive power consists of (i) 121,775 Shares issuable upon exercise of the Bios Directors Options, (ii) 574,432 Shares directly held by Bios Fund II, (iii) 1,876,624 Shares directly held by Bios Fund II QP, (iv) 251,211 Shares directly held by Bios Fund II NT, (v) 997,433 Shares directly held by BIOS Incysus, (vi) ) 570,724 Shares directly held by Bios Fund III, (vii) 3,727,597 Shares directly held by Bios Fund III QP and (viii) 601,980 Shares directly held by Bios Fund III NT, in each case, as of the date hereof. Bios Equity Partners I is the general partner of Bios Directors. Bios Equity Partners II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively the "Bios Equity II Entities"). Bios Equity Partners III is the general partner of Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively the "Bios Equity III Entities"). Cavu Management, LP ("Cavu Management") is a general partner of Bios Equity I, Bios Equity II and Bios Equity III. In its capacity as a general partner of Bios Equity I, Bios Equity II and Bios Equity III, Cavu Management may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by Bios Directors, the Bios Equity II Entities and the Bios Equity III Entities. Percentage based on 90,893,719 Shares, consisting of (i) 90,771,944 Shares outstanding as of May 2, 2025, provided by Issuer, and (ii) 121,775 Shares issuable upon exercise of the Bios Directors Options. 0001813845 N BIOS CAPITAL MANAGEMENT, LP b AF N TX 0.00 9120073.00 0.00 9120073.00 9120073.00 Y 9.99 PN Shared voting and dispositive power consists of (i) 121,775 Shares issuable upon exercise of the Bios Directors Options, (ii) 574,432 Shares directly held by Bios Fund II, (iii) 1,876,624 Shares directly held by Bios Fund II QP, (iv) 251,211 Shares directly held by Bios Fund II NT, (v) 997,433 Shares directly held by BIOS Incysus, (vi) ) 570,724 Shares directly held by Bios Fund III, (vii) 3,727,597 Shares directly held by Bios Fund III QP, (viii) 601,980 Shares directly held by Bios Fund III NT, and (ix) 398,297 Shares issuable upon exercise of the Bios COF Warrants, in each case, as of the date hereof. Excludes a total of 2,742,506 Shares issuable upon the exercise of the Bios COF Warrants that are not currently exercisable due to the Beneficial Ownership Limitation. Bios Equity Partners I is the general partner of Bios Directors. Bios Equity Partners II is the general partner of the Bios II Entities. Bios Equity Partners III is the general partner of the Bios III Entities. Bios Equity COF is the general partner of Bios COF. Bios Capital Management, LP ("Bios Management") is a general partner of Bios Equity I, Bios Equity II, Bios Equity III, and is the general partner of Bios Equity COF. In its capacity as a general partner of Bios Equity I, Bios Equity II and Bios Equity III and the general partner of Bios Equity COF, Bios Management may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by Bios Directors, the Bios Equity II Entities, the Bios Equity III Entities and Bios COF. Percentage based on 91,292,016 Shares, consisting of (i) 90,771,944 Shares outstanding as of May 2, 2025, provided by Issuer, (ii) 121,775 Shares issuable upon exercise of the Bios Directors Options, and (iii) 398,297 Shares issuable upon exercise of the Bios COF Warrants. 0001813310 N CAVU ADVISORS, LLC b AF N TX 0.00 8721776.00 0.00 8721776.00 8721776.00 N 9.6 PN Shared voting and dispositive power consists of (i) 121,775 Shares issuable upon exercise of the Bios Directors Options, (ii) 574,432 Shares directly held by Bios Fund II, (iii) 1,876,624 Shares directly held by Bios Fund II QP, (iv) 251,211 Shares directly held by Bios Fund II NT, (v) 997,433 Shares directly held by BIOS Incysus, (vi) ) 570,724 Shares directly held by Bios Fund III, (vii) 3,727,597 Shares directly held by Bios Fund III QP and (viii) 601,980 Shares directly held by Bios Fund III NT, in each case, as of the date hereof. Bios Equity Partners I is the general partner of Bios Directors. Bios Equity Partners II is the general partner of the Bios II Entities. Bios Equity Partners III is the general partner the Bios III Entities. Cavu Management, LP is a general partner of Bios Equity I, Bios Equity II, and Bios Equity III. Cavu Advisors, LLC ("Cavu Advisors") is the general partner of Cavu Management, and therefore may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by the Bios Directors, the Bios Equity II Entities and the Bios Equity III Entities. Percentage based on 90,893,719 Shares, consisting of (i) 90,771,944 Shares outstanding as of May 2, 2025, provided by Issuer, and (ii) 121,775 Shares issuable upon exercise of the Bios Directors Options. 0001813844 N BIOS ADVISORS GP, LLC b AF N TX 0.00 9120073.00 0.00 9120073.00 9120073.00 Y 9.9 PN Shared voting and dispositive power consists of (i) 121,775 Shares issuable upon exercise of the Bios Directors Options, (ii) 574,432 Shares directly held by Bios Fund II, (iii) 1,876,624 Shares directly held by Bios Fund II QP, (iv) 570,724 Shares directly held by Bios Fund II NT, (v) 997,433 Shares directly held by BIOS Incysus, (vi) ) 570,724 Shares directly held by Bios Fund III, (vii) 2,742,506 Shares directly held by Bios Fund III QP (viii) 601,980 Shares directly held by Bios Fund III NT, and (ix) 398,297 Shares issuable upon exercise of the Bios COF Warrants, in each case, as of the date hereof. Excludes a total of 3,140,803 Shares issuable upon the exercise of the Bios COF Warrants that are not currently exercisable due to the Beneficial Ownership Limitation. Bios Equity Partners I is the general partner of Bios Directors. Bios Equity Partners II is the general partner of the Bios II Entities. Bios Equity Partners III is the general partner of the Bios III Entities. Bios Equity COF is the general partner of Bios COF. Bios Management is a general partner of Bios Equity I, Bios Equity II and Bios Equity III, and is the general partner of Bios Equity COF. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by Bios Directors, the Bios Equity II Entities, the Bios Equity III Entities and Bios COF. Percentage based on 91,292,016 Shares, consisting of (i) 90,771,944 Shares outstanding as of May 2, 2025, provided by Issuer, (ii) 121,775 Shares issuable upon exercise of the Bios Directors Options, and (iii) 398,297 Shares issuable upon exercise of the Bios COF Warrants. 0001813316 N LESLIE W. KREIS b AF OO N X1 0.00 8721776.00 0.00 8721776.00 8721776.00 N 9.6 IN Shared voting and dispositive power consists of (i) 121,775 Shares issuable upon exercise of the Bios Directors Options, (ii) 574,432 Shares directly held by Bios Fund II, (iii) 1,876,624 Shares directly held by Bios Fund II QP, (iv) 251,211 Shares directly held by Bios Fund II NT, (v) 997,433 Shares directly held by BIOS Incysus, (vi) ) 570,724 Shares directly held by Bios Fund III, (vii) 3,727,597 Shares directly held by Bios Fund III QP and (viii) 601,980 Shares directly held by Bios Fund III NT, in each case, as of the date hereof. Bios Equity Partners I is the general partner of Bios Directors. Bios Equity Partners II is the general partner of the Bios II Entities. Bios Equity Partners III is the general partner the Bios III Entities. Cavu Management, LP is a general partner of Bios Equity I, Bios Equity II, and Bios Equity III. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by Bios Directors, the Bios Equity II Entities and the Bios Equity III Entities. Percentage based on 90,893,719 Shares, consisting of (i) 90,771,944 Shares outstanding as of May 2, 2025, provided by Issuer, and (ii) 121,775 Shares issuable upon exercise of the Bios Directors Options. 0001789490 N AARON G.L. FLETCHER b AF OO N X1 0.00 9120073.00 0.00 9120073.00 9120073.00 Y 9.99 PN Shared voting and dispositive power consists of (i) 121,775 Shares issuable upon exercise of the Bios Directors Options, (ii) 574,432 Shares directly held by Bios Fund II, (iii) 1,876,624 Shares directly held by Bios Fund II QP, (iv) 251,211 Shares directly held by Bios Fund II NT, (v) 997,433 Shares directly held by BIOS Incysus, (vi) ) 570,724 Shares directly held by Bios Fund III, (vii) 3,727,597 Shares directly held by Bios Fund III QP (viii) 601,980 Shares directly held by Bios Fund III NT, and (ix) 398,297 Shares issuable upon exercise of the Bios COF Warrants, in each case, as of the date hereof. Excludes a total of 2,742,506 Shares issuable upon the exercise of the Bios COF Warrants that are not currently exercisable due to the Beneficial Ownership Limitation. Bios Equity Partners I is the general partner of Bios Directors. Bios Equity Partners II is the general partner of the Bios II Entities. Bios Equity Partners III is the general partner of the Bios III Entities. Bios Equity COF is the general partner of Bios COF. Bios Management is a general partner of Bios Equity I, Bios Equity II and Bios Equity III, and is the general partner of Bios Equity COF. Bios Advisors, an entity controlled by Dr. Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by Bios Directors, the Bios Equity II Entities, the Bios Equity III Entities and Bios COF. Percentage based on 91,292,016 Shares, consisting of (i) 90,771,944 Shares outstanding as of May 2, 2025, provided by Issuer, (ii) 121,775 Shares issuable upon exercise of the Bios Directors Options and (iii) 389,297 Shares issuable upon exercise of Bios COF Warrants. Common Stock, par value $0.0001 per share IN8bio, Inc. EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 The information contained in Item 6 is incorporated herein by reference. The closing of the transactions contemplated by the Warrant Exchange Agreement took place on May 2, 2025. Bios COF acquired the Pre-Funded Warrants (i) using cash from working capital from capital contributions and funds from lines of credit entered into in the ordinary course of business and (ii) through the surrender for cancellation of the Series A Warrants and Series B Warrants. The information contained on the cover pages of this Schedule 13D is incorporated herein by reference. The information contained on the cover pages of this Schedule 13D is incorporated herein by reference. Except as otherwise disclosed in Item 6 below, none of the Reporting Persons, nor, to the best of the Reporting Persons' knowledge, any of their respective executive officers or directors, as applicable, has acquired or disposed of, any securities of the Issuer during the 60 days prior to the date hereof. Pursuant to a Warrant Exchange Agreement (the "Warrant Exchange Agreement"), dated as of April 26, 2025, between the Issuer and Bios COF, Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the "Pre-Funded Warrants") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock (the "Series A Warrants"), (ii) 574,241 Series B Warrants to purchase one share of Common Stock (the "Series B Warrants") and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrants are exercised in full.; provided, however, that the exercise of such Pre-Funded Warrants is subject to a 9.99% beneficial ownership limitation. The summary of the Warrant Exchange Agreement contained herein is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed as an exhibit hereto. Exhibit 99.1: Joint Filing Agreement (incorporated by reference to Exhibit 99.1 of Amendment No. 1, filed December 15, 2023) Exhibit 99.2: Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 1, 2024) Exhibit 99.3: Form of Series C Warrant (incorporated by reference to Exhibit 4.2 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 1, 2024) Exhibit 99.4: 2024 Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 1, 2024) Exhibit 99.5: Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 28, 2025) Exhibit 99.6: Amendment No. 1 to 2024 Stock Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 28, 2025) Exhibit 99.7: Warrant Exchange Agreement (incorporated by reference to Exhibit 10.3 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 28, 2025) BIOS FUND II, LP /s/ Daniel Schwarz Daniel Schwarz/Attorney-in-Fact 05/07/2025 BIOS FUND II QP, LP /s/ Daniel Schwarz Daniel Schwarz/Attorney-in-Fact 05/07/2025 BIOS FUND II NT, LP /s/ Daniel Schwarz Daniel Schwarz/Attorney-in-Fact 05/07/2025 BIOS INCYSUS CO-INVEST I, LP /s/ Daniel Schwarz Daniel Schwarz/Attorney-in-Fact 05/07/2025 BIOS FUND III, LP /s/ Daniel Schwarz Daniel Schwarz/Attorney-in-Fact 05/07/2025 BIOS FUND III QP, LP /s/ Daniel Schwarz Daniel Schwarz/Attorney-in-Fact 05/07/2025 BIOS FUND III NT, LP /s/ Daniel Schwarz Daniel Schwarz/Attorney-in-Fact 05/07/2025 BIOS CLINICAL OPPORTUNITY FUND, LP /s/ Daniel Schwarz Daniel Schwarz/Attorney-in-Fact 05/07/2025 BP DIRECTORS, LP /s/ Daniel Schwarz Daniel Schwarz/Attorney-in-Fact 05/07/2025 BIOS EQUITY PARTNERS, LP /s/ Daniel Schwarz Daniel Schwarz/Attorney-in-Fact 05/07/2025 BIOS EQUITY PARTNERS II, LP /s/ Daniel Schwarz Daniel Schwarz/Attorney-in-Fact 05/07/2025 BIOS EQUITY PARTNERS III, LP /s/ Daniel Schwarz Daniel Schwarz/Attorney-in-Fact 05/07/2025 BIOS EQUITY COF, LP /s/ Daniel Schwarz Daniel Schwarz/Attorney-in-Fact 05/07/2025 CAVU MANAGEMENT, LP /s/ Daniel Schwarz Daniel Schwarz/Attorney-in-Fact 05/07/2025 BIOS CAPITAL MANAGEMENT, LP /s/ Daniel Schwarz Daniel Schwarz/Attorney-in-Fact 05/07/2025 CAVU ADVISORS, LLC /s/ Daniel Schwarz Daniel Schwarz/Attorney-in-Fact 05/07/2025 BIOS ADVISORS GP, LLC /s/ Daniel Schwarz Daniel Schwarz/Attorney-in-Fact 05/07/2025 LESLIE W. KREIS /s/ Daniel Schwarz DANIEL SCHWARZ, as Attorney-in-Fact for Leslie W. Kreis, Jr. 05/07/2025 AARON G.L. FLETCHER /s/ Daniel Schwarz DANIEL SCHWARZ, as Attorney-in-Fact for Aaron G.L. Fletcher 05/07/2025 BIOS FUND II, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ Daniel Schwarz Daniel Schwarz Attorney-in-Fact BIOS FUND II QP, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ Daniel Schwarz Daniel Schwarz Attorney-in-Fact BIOS FUND II NT, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ Daniel Schwarz Daniel Schwarz Attorney-in-Fact BIOS INCYSUS CO-INVEST I, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ Daniel Schwarz Daniel Schwarz Attorney-in-Fact BIOS FUND III, LP By: Bios Equity Partners III, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ Daniel Schwarz Daniel Schwarz Attorney-in-Fact BIOS FUND III QP, LP By: Bios Equity Partners III, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ Daniel Schwarz Daniel Schwarz Attorney-in-Fact BIOS FUND III NT, LP By: Bios Equity Partners III, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ Daniel Schwarz Daniel Schwarz Attorney-in-Fact BIOS CLINICAL OPPORTUNITY FUND, LP By: Bios Equity COF, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner BP DIRECTORS, LP By: Bios Equity Partners, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ Daniel Schwarz Daniel Schwarz Attorney-in-Fact BIOS EQUITY PARTNERS, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ Daniel Schwarz Daniel Schwarz Attorney-in-Fact BIOS EQUITY PARTNERS II, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ Daniel Schwarz Daniel Schwarz Attorney-in-Fact BIOS EQUITY PARTNERS III, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ Daniel Schwarz Daniel Schwarz Attorney-in-Fact BIOS EQUITY COF, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner CAVU MANAGEMENT, LP By: Cavu Advisors, LLC, its general partner By: /s/ Daniel Schwarz Attorney-in-Fact BIOS CAPITAL MANAGEMENT, LP By: Bios Advisors GP, LLC its general partner By: /s/ Daniel Schwarz Attorney-in-Fact